BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37735118)

  • 21. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
    Liu J; Li G
    Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of m
    Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
    Front Immunol; 2022; 13():955848. PubMed ID: 36203569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
    Zhang X; Sun X; Guo C; Li J; Liang G
    Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
    Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
    Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
    Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
    Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
    Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lactate-induced up-regulation of PLEKHA4 promotes proliferation and apoptosis of human glioma cells].
    Ye J; Xu W; Xi B; Wang N; Chen T
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jul; 43(7):1071-1080. PubMed ID: 37488789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
    Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
    Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma.
    Wang Z; Aili Y; Wang Y; Maimaitiming N; Qin H; Ji W; Fan G; Li B
    Oxid Med Cell Longev; 2022; 2022():7967722. PubMed ID: 35993018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
    Wu Y; Peng Z; Gu S; Wang H; Xiang W
    Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.
    Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T
    Front Immunol; 2019; 10():1756. PubMed ID: 31428092
    [No Abstract]   [Full Text] [Related]  

  • 39. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
    Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
    J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
    Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
    Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.